For the past several years, a flurry of psychedelic-related research has found that hallucinogenic drugs have various applications in the mental health field. Researchers have found that pairing talk therapy with psychedelics is incredibly effective at alleviating conditions such as depression, anxiety and post-traumatic stress disorder.
Several years after psychedelics began gaining steam as alternative mental health treatments, the U.S. Food and Drugs Administration has finally issued guidance on the management of psychedelic clinical trials. Even though initial results have been incredibly encouraging, significantly more research and clinical trials are needed before psychedelic-based treatments are developed and deployed to the mass market.
The draft guidance published by the FDA in late June 2023 is meant to provide protocols and regulations for future clinical trials involving psychedelics. It offers guidance on the creation of clinical studies to study hallucinogenics such as LSD, psilocybin (magic mushrooms) and MDMA along with their effectiveness in mental health treatment.
According to a statement from an FDA spokesperson, psychedelics present a “very active and challenging area of drug development.” The agency spokesperson noted that there is limited experience in creating programs to study psychedelics for FDA approval due to the novelty of the field.
Compass Pathways, one of the largest companies taking part in psychedelic research, had revealed that it was expecting the draft guidance based on past communications with the FDA. The company is currently running phase 3 studies on the safety and efficacy of psilocybin, the main psychoactive component in magic mushrooms. A Compass Pathways spokesperson said that the company is pleased to see that the draft guidance from the regulatory agency is in line with its own policies, especially on rigor and exceedingly high standards.
Pathways’ clinical trials are already designed with similar protocols in mind and will not need any further change in the face of the draft regulations, the spokesperson said. Researchers in academic institutions studying psychedelics have also praised the draft regulations, stating that they provide much-needed guidance for the nascent but swiftly growing field of psychedelic research.
However, some experts are not pleased with certain requirements included in the draft provisions such as a recommendation that psychedelic clinical trial subjects must be observed by two monitors during treatment. One of the monitors should be a healthcare professional with “graduate-level professional training” and psychotherapy experience and the other should have a degree and at least one year of clinical experience in mental healthcare.
Paul Hutson, PharmD, MS, director of the Transdisciplinary Center for Research in Psychoactive Substances at the University of Wisconsin in Madison, that this will be one of the most disputed aspects of the draft regulations. Hutson explained that the provision could derail efforts to study psychedelics by overburdening research teams.
More views on the research guidelines can be expected from enterprises such as Seelos Therapeutics Inc. (NASDAQ: SEEL) as the comment period progresses.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.